Viewing data from:

NAPROXEN

ANDA

NAPROXEN | A218497 | NOVITIUM PHARMA LLC

2 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: EC-NAPROSYN(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$2.34

per ea

Lowest NADAC/Unit

$1.93

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
70954092510NAPROXEN DR 375 MG TABLET	$2.34	EA	Generic	—	2026-06-17
70954092810NAPROXEN DR 500 MG TABLET	$1.93	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain8 active DMFs13 inactive

7 active API suppliers hold Drug Master Files for this ingredient.

DR REDDYS LABORATORIES LTDNAPROXEN

DMF 20301972

TAPI NL BVNAPROXEN

DMF 87481990

DR REDDYS LABORATORIES LTDNAPROXEN

DMF 123411997

DIVIS LABORATORIES LTDNAPROXEN USP

DMF 138661998

ZHEJIANG CHARIOTEER PHARMACEUTICAL CO LTDNAPROXEN USP (BULK)

DMF 185542005

APITORIA PHARMA PRIVATE LTDNAPROXEN USP (NON STERILE DRUG SUBSTANCE)

DMF 227542009

SOLARA ACTIVE PHARMA SCIENCES LTDNAPROXEN USP

DMF 382372023

HETERO LABS LTDNAPROXEN

DMF 389302023

BLASCHIM SPAInactiveNAPROXEN

DMF 47501982

DINAMITE DIPHARMA SPAInactiveNAPROXEN USP XX BP 80

DMF 48781983

ZAMBON SPAInactiveNAPROXEN USP

DMF 68721987

RALLIS INDIA LTDInactiveNAPROXEN

DMF 71351987

BENZEX LABORATORIES LTDInactiveNAPROXEN

DMF 76161988

CORDEN PHARMA BERGAMO SPAInactiveNAPROXEN USP

DMF 118281996

ALBEMARLE CORPInactiveNAPROXEN (RACEMIC)

DMF 119391996

ALBEMARLE CORPInactiveNAPROXEN

DMF 119411996

HUBEI PHARMACEUTICAL FACTORYInactiveNAPROXEN USP

DMF 126301997

NATCO PHARMA LTDInactiveNAPROXEN, USP

DMF 128911998

SOLARA ACTIVE PHARMA SCIENCES LTDInactiveNAPROXEN, USP

DMF 138821998

TEVA GROUPInactiveNAPROXEN AND NAPROXEN SODIUM USP

DMF 156272001

MYLAN LABORATORIES LTDInactiveNAPROXEN USP

DMF 162462002

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 375MG

0 patents0 exclusivities▴

TABLET, DELAYED RELEASE;ORAL | Approved: Jun 12, 2024

No patent or exclusivity listings for this strength.

#002 — 500MG

0 patents0 exclusivities▾

TABLET, DELAYED RELEASE;ORAL | Approved: Jun 12, 2024